Date Is Set for Merger Between Mylan and Pfizer's Upjohn Unit

Date Is Set for Merger Between Mylan and Pfizer's Upjohn Unit

The merger of Pfizer's (NYSE: PFE) generic drug business, Upjohn, with Mylan (NASDAQ: MYL) will be going through shortly, now that the companies have agreed to a consent order with the U.S. Federal Trade Commission. The companies didn't give any details about what they had agreed to do in order to comply with that consent order. On Nov. 13, Pfizer will spin off Upjohn, and its shareholders will receive stock in the new company.